Premium
An overview of epigenetics and chemoprevention
Author(s) -
Huang Yi-Wen,
Kuo Chieh-Ti,
Stoner Kristen,
Huang Tim H.-Y.,
Wang Li-Shu
Publication year - 2011
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2010.11.002
Subject(s) - epigenetics , epigenome , dna methylation , cancer epigenetics , histone deacetylase , histone , biology , methyltransferase , epigenetic therapy , genetics , cancer , bioinformatics , computational biology , cancer research , dna , methylation , histone methyltransferase , gene , gene expression
It is now appreciated that both genetic alteration, e.g. mutations, and aberrant epigenetic changes, e.g. DNA methylation, cause cancer. Epigenetic dysregulation is potentially reversible which makes it attractive as targets for cancer prevention. Synthetic drugs targeting enzymes, e.g. DNA methyltransferase and histone deacetylase, that regulate epigenetic patterns are active in clinical settings. In addition, dietary factors have been suggested to have potential to reverse aberrant epigenetic patterns. Uncovering the human epigenome can lead us to better understand the dynamics of DNA methylation in disease progression which can further assist in cancer prevention.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom